The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 178 of the 179 references it cites were found in a registry or an index.
Abstract
Cholinergic synapses are ubiquitous in the human central nervous system. Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions. Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity. As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease. The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation. Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation. Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease. This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins. This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies. The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The FDA approved two anti-amyloid immunotherapies, lecanemab and donanemab, for “early-stage” AD, encompassing both stage 3 (MCI) and stage 4 (mild dementia).”
From A 2025 update on treatment strategies for the Alzheimer’s disease spectrum (2025) · cites this paper as [18]
In the citing paper
“Degeneration of cholinergic neurons is known to significantly contribute to cognitive decline in AD patients [132] and has been studied in a variety of genetic AD mouse models.”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [132]
In the citing paper
“AChE contributes to acetylcholine depletion and may facilitate the formation of neurotoxic Aβ-AChE complexes38.”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [38]
In the citing paper
“Cholinergic deficit also alters the permeability of the blood brain barrier causing erroneous transportation of metabolites and hampering the removal of amyloid plaque, worsening the disease condition [8].”
From Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease (2020) · cites this paper as [8]
In the citing paper
“From this point of view, AD could be prevented or effectively treated by decreasing the production of Aβ and tau; preventing aggregation or misfolding of these proteins; neutralizing or removing the toxic aggregate or misfolded forms of these proteins; or a combination of these modalities.7”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [7]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
Human Memory and the Cholinergic System: A Relationship to Aging?
Drachman, D. A. (1974) · Archives of Neurology · doi:10.1001/archneur.1974.00490320001001 · Cited by 1,397
NEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311
Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,290
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 2×
“, 1995) followed by the "4 allele of apolipoprotein E (APOE "4) (Liu et al., 2013; Shi et al., 2017), and probably also cardiovascular and”
BackgroundOral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type
Summers, W. K., Majovski, L. V., Marsh, G. M., Tachiki, K., & Kling, A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611133152001 · Cited by 1,163
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139
Self-citationCumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study
Gray, S. L., Anderson, M. L., Dublin, S., Hanlon, J. T., Hubbard, R., Walker, R., Yu, O., Crane, P. K., & Larson, E. B. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.7663 · Cited by 1,111 · cited 1×
“Thus, higher estimates of cumulative exposure to anticholinergic therapies were associated with a greater risk for incident dementia or Alzheimer’s disease dementia than were lower levels of cumulative anticholinergic exposure (Gray et al., 2015).”
BackgroundNECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
The cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760
Neurotransmitter enzyme abnormalities in senile dementia
Perry, E. K., Gibson, P. H., Blessed, G., Perry, R. H., & Tomlinson, B. E. (1977) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(77)90073-9 · Cited by 724
Mash, D. C., Flynn, D. D., & Potter, L. T. (1985) · Science · doi:10.1126/science.3992249 · Cited by 698
Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2008) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 672
A neural circuit for circadian regulation of arousal
Aston-Jones, G., Chen, S., Zhu, Y., & Oshinsky, M. L. (2001) · Nature Neuroscience · doi:10.1038/89522 · Cited by 632 · cited 1×
“It is also interesting to highlight that acetylcholine is one of the core neuromodulators involved in the regulation of the sleep-wake cycle, the preservation of which has been reported to be essential for many cognitive functions related to memory processes (Aston-Jones et al., 2001; Power, 2004).”
BackgroundCholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Bierer, L. M., Haroutunian, V., Gabriel, S., Knott, P. J., Carlin, L. S., Purohit, D. P., Perl, D. P., Schmeidler, J., Kanof, P., & Davis, K. L. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020749.x · Cited by 580
Salahudeen, M. S., Duffull, S. B., & Nishtala, P. S. (2015) · BMC Geriatrics · doi:10.1186/s12877-015-0029-9 · Cited by 547
Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 492
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence
McNamara, C. G., Tejero-Cantero, Á., Trouche, S., Campo-Urriza, N., & Dupret, D. (2014) · Nature Neuroscience · doi:10.1038/nn.3843 · Cited by 486
Age-Specific Incidence of Alzheimer's Disease in a Community Population
Hebert, L. E. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520410048025 · Cited by 475
Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease
Mesulam, M. ‐. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23415 · Cited by 375
Self-citationCholinergic nucleus basalis tauopathy emerges early in the aging‐MCI‐AD continuum
Mesulam, M., Shaw, P., Mash, D., & Weintraub, S. (2004) · Annals of Neurology · doi:10.1002/ana.20100 · Cited by 374
Self-citationVascular, glial, and lymphatic immune gateways of the central nervous system
Engelhardt, B., Carare, R. O., Bechmann, I., Flügel, A., Laman, J. D., & Weller, R. O. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1606-5 · Cited by 362 · cited 1×
“perivascular lymphatic drainage of amyloid-b (Engelhardt et al., 2016).”
Nordberg, A., & Winblad, B. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90629-4 · Cited by 361
Ruxton, K., Woodman, R. J., & Mangoni, A. A. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12617 · Cited by 360
O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
Risacher, S. L., McDonald, B. C., Tallman, E. F., West, J. D., Farlow, M. R., Unverzagt, F. W., Gao, S., Boustani, M., Crane, P. K., Petersen, R. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0580 · Cited by 350 · cited 1×
“Among cognitively healthy individuals in the ADNI (Alzheimer Disease Neuroimaging Initiative) and Indiana Memory and Aging Study, the 52 participants who had been regularly taking one or more medications with medium or high anticholinergic activity prior to study entry demonstrated worse immediate recall and executive…”
BackgroundSelf-citationAlzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339
Fox, C., Smith, T., Maidment, I., Chan, W.-Y., Bua, N., Myint, P. K., Boustani, M., Kwok, C. S., Glover, M., Koopmans, I., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu096 · Cited by 336
Feldman, H. H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., Tekin, S., Burns, A., Cummings, J., del Ser, T., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70109-6 · Cited by 335
Self-citationBasal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
Schmitz, T. W., Nathan Spreng, R., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., Toga, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13249 · Cited by 335
Self-citationFarlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332 · cited 1×
“For example, in placebo-controlled studies of rivastigmine, an initial 26-week phase was followed by a 26-week openlabel extension in which all patients received rivastigmine (Farlow et al., 2000; Doraiswamy et al., 2002).”
MethodSelf-citationCardiovascular risk factors and future risk of Alzheimer’s disease
de Bruijn, R. F., & Ikram, M. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0130-5 · Cited by 322
Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial
Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., & Richardson, S. (2004) · Neurology · doi:10.1212/01.wnl.0000134664.80320.92 · Cited by 300
Plasticity of temporal information processing in the primary auditory cortex
Kilgard, M. P., & Merzenich, M. M. (1998) · Nature Neuroscience · doi:10.1038/3729 · Cited by 298
Safety and efficacy of galantamine in subjects with mild cognitive impairment
Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303815.69777.26 · Cited by 266
Loss of functional GABA A receptors in the Alzheimer diseased brain
Limon, A., Reyes-Ruiz, J. M., & Miledi, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204606109 · Cited by 264
Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.676 · Cited by 242
Beaulieu, J.-M. (2012) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.110011 · Cited by 238
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230 · cited 1×
“Prospective long-term observational studies suggest that cholinesterase inhibitors offer a benefit over the longterm course of Alzheimer’s disease (Atri et al., 2008).”
BackgroundStop Alzheimer’s before it starts
McDade, E., & Bateman, R. J. (2017) · Nature · doi:10.1038/547153a · Cited by 230
Apathy associated with neurocognitive disorders: Recent progress and future directions
Lanctôt, K. L., Agüera‐Ortiz, L., Brodaty, H., Francis, P. T., Geda, Y. E., Ismail, Z., Marshall, G. A., Mortby, M. E., Onyike, C. U., Padala, P. R., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.008 · Cited by 217
Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 213
Cholinergic Neuronal and Axonal Abnormalities Are Present Early in Aging and in Alzheimer Disease
Geula, C., Nagykery, N., Nicholas, A., & Wu, C.-K. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816a1df3 · Cited by 202
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Emir, B., Mastey, V., Subbiah, P., & The Donepezil MSAD Study Investigators Group (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51260.x · Cited by 202
Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert
Sassin, I., Schultz, C., Thal, D. R., Rüb, U., Arai, K., Braak, E., & Braak, H. (2000) · Acta Neuropathologica · doi:10.1007/s004019900178 · Cited by 195
DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 195
Cholinergic stimulation enhances long-term potentiation in the CA1 region of rat hippocampus
Blitzer, R. D., Gil, O., & Landau, E. M. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90835-w · Cited by 192 · cited 1×
“The application of cholinergic agonists and antagonists to rat hippocampal slices has clarified the role for acetylcholine in long-term potentiation (Blitzer et al., 1990; Auerbach and Segal, 1996).”
BackgroundFarlow, M. R., Salloway, S., Tariot, P. N., Yardley, J., Moline, M. L., Wang, Q., Brand-Schieber, E., Zou, H., Hsu, T., & Satlin, A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.019 · Cited by 186
Self-citationRountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181 · cited 1×
“At least two other prospective observational Alzheimer’s disease studies offer similar results, demonstrating slower cognitive and functional deterioration with the persistent and continued use of cholinesterase inhibitors (Rountree et al., 2009; Gillette-Guyonnet et al., 2011).”
ResultModulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders
Kalkman, H. O., & Feuerbach, D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2175-4 · Cited by 181
Hunter, J. M., Kwan, J., Malek-Ahmadi, M., Maarouf, C. L., Kokjohn, T. A., Belden, C., Sabbagh, M. N., Beach, T. G., & Roher, A. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036893 · Cited by 178
Scopolamine induced learning failures in man
Petersen, R. C. (1977) · Psychopharmacology · doi:10.1007/bf00426713 · Cited by 172
M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Jiang, S., Li, Y., Zhang, C., Zhao, Y., Bu, G., Xu, H., & Zhang, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1406-z · Cited by 170
Cholinesterase inhibitors for mild cognitive impairment
Russ, T. C., & Morling, J. R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009132.pub2 · Cited by 168
Muscarinic receptors mediating depression and long‐term potentiation in rat hippocampus.
Auerbach, J. M., & Segal, M. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021323 · Cited by 168
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00258-6 · Cited by 165
Field, R. H., Gossen, A., & Cunningham, C. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4673-11.2012 · Cited by 164
O’Brien, J. T., & Burns, A. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110387547 · Cited by 164
Update on the Pharmacological Treatment of Alzheimers Disease
Massoud, F., & Gauthier, S. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 163
Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
Mori, F., Lai, C.-C., Fusi, F., & Giacobini, E. (1995) · NeuroReport · doi:10.1097/00001756-199503000-00012 · Cited by 157
Self-citationBeach, T. G., Kuo, Y.-M., Spiegel, K., Emmerling, M. R., Sue, L. I., Kokjohn, K., & Roher, A. E. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.4.308 · Cited by 154
Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease
Schro¨der, H., Ezio, G., Struble, R. G., Zilles, K., & Maelicke, A. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90107-u · Cited by 150
Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome
Iulita, M. F., & Cuello, A. C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.010 · Cited by 149
Self-citationTargeting norepinephrine in mild cognitive impairment and Alzheimer's disease
Chalermpalanupap, T., Kinkead, B., Hu, W. T., Kummer, M. P., Hammerschmidt, T., Heneka, M. T., Weinshenker, D., & Levey, A. I. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt175 · Cited by 145
Sittironnarit, G., Ames, D., Bush, A. I., Faux, N., Flicker, L., Foster, J., Hilmer, S., Lautenschlager, N. T., Maruff, P., Masters, C. L., et al. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000325171 · Cited by 144
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease
Dubois, B., Chupin, M., Hampel, H., Lista, S., Cavedo, E., Croisile, B., Louis Tisserand, G., Touchon, J., Bonafe, A., Ousset, P. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.10.003 · Cited by 140
Self-citationPreclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
Mills, S. M., Mallmann, J., Santacruz, A. M., Fuqua, A., Carril, M., Aisen, P. S., Althage, M. C., Belyew, S., Benzinger, T. L., Brooks, W. S., et al. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.017 · Cited by 139
Self-citationTricco, A. C., Ashoor, H. M., Soobiah, C., Rios, P., Veroniki, A. A., Hamid, J. S., Ivory, J. D., Khan, P. A., Yazdi, F., Ghassemi, M., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15069 · Cited by 137
Cholinergic Involvement in Alzheimer’s Disease. A Link with NGF Maturation and Degradation
Cuello, A. C., Bruno, M. A., Allard, S., León, W., & Iulita, M. F. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9238-z · Cited by 135
Self-citationEffect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease
Geaney, D. P., Soper, N., SHEPSTONE, B. J., & Cowen, P. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)93028-n · Cited by 132
Wattmo, C., Wallin, A. K., Londos, E., & Minthon, L. (2011) · The Gerontologist · doi:10.1093/geront/gnq050 · Cited by 125
Rapid β-Amyloid Deposition and Cognitive Impairment After Cholinergic Denervation in APP/PS1 Mice
Ramos-Rodriguez, J. J., Pacheco-Herrero, M., Thyssen, D., Murillo-Carretero, M. I., Berrocoso, E., Spires-Jones, T. L., Bacskai, B. J., & Garcia-Alloza, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318288a8dd · Cited by 125
Alzheimer Disease: from Molecular Biology to Therapy
Giacobini, E. (1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)85593-x · Cited by 120
Self-citationThe effects and interactions of scopolamine, physostigmine and methamphetamine on human memory
Mewaldt, S. P., & Ghoneim, M. M. (1979) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(79)90088-1 · Cited by 120
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 116
Szutowicz, A., Bielarczyk, H., Jankowska-Kulawy, A., Pawełczyk, T., & Ronowska, A. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1060-x · Cited by 115
Neurochemical basis for symptomatic treatment of Alzheimer's disease
Francis, P. T., Ramírez, M. J., & Lai, M. K. P. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.02.010 · Cited by 115
Nucleus Accumbens Acetylcholine Receptors Modulate Dopamine and Motivation
Collins, A. L., Aitken, T. J., Greenfield, V. Y., Ostlund, S. B., & Wassum, K. M. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.81 · Cited by 113
Mechanism of action of scopolamine as an amnestic
Izquierdo, I. (1989) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(89)90231-9 · Cited by 110
Cholinergic modulation of multivesicular release regulates striatal synaptic potency and integration
Higley, M. J., Soler-Llavina, G. J., & Sabatini, B. L. (2009) · Nature Neuroscience · doi:10.1038/nn.2368 · Cited by 110 · cited 1×
“For example, the activity of presynaptic 7 nicotinic receptor may facilitate glutamate release, while activation of muscarinic receptors may decrease both the release and the concentration of glutamate in the synaptic cleft (Higley et al., 2009).”
BackgroundCavedo, E., Grothe, M. J., Colliot, O., Lista, S., Chupin, M., Dormont, D., Houot, M., Lehéricy, S., Teipel, S., Dubois, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09780-3 · Cited by 109
Self-citationThe cerebrovascular role of the cholinergic neural system in Alzheimer's disease
van Beek, A. H. E. A., & Claassen, J. A. H. R. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.047 · Cited by 106
Relationship between plaques, tangles, and loss of cortical cholinergic fibers in alzheimer disease
Geula, C., Mesulam, M. M., Saroff, D. M., & Wu, C.-K. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199801000-00008 · Cited by 102
Self-citationNerve Growth Factor and Alzheimer's Disease: New Facts for an Old Hypothesis
Cattaneo, A., & Calissano, P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8310-9 · Cited by 101
Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’ disease
Giacobini, E. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_17 · Cited by 100
Self-citationToward precision medicine in Alzheimer’s disease
Reitz, C. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.05 · Cited by 100
Iulita, M. F., Ower, A., Barone, C., Pentz, R., Gubert, P., Romano, C., Cantarella, R. A., Elia, F., Buono, S., Recupero, M., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.05.001 · Cited by 99
Self-citationCerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease
Venneri, A., Shanks, M. F., Staff, R. T., Pestell, S. J., Forbes, K. E., Gemmell, H. G., & Murray, A. D. (2002) · Neuroreport · doi:10.1097/00001756-200201210-00020 · Cited by 98
Pouryamout, L., Dams, J., Wasem, J., Dodel, R. C., & Neumann, A. (2012) · Drugs · doi:10.2165/11631830-000000000-00000 · Cited by 94
Potter, P. E., Rauschkolb, P. K., Pandya, Y., Sue, L. I., Sabbagh, M. N., Walker, D. G., & Beach, T. G. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0831-1 · Cited by 94
Chu, J., Lauretti, E., & Praticò, D. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.214 · Cited by 94
Lacombe, P. M., Sercombe, R., VERRECCHIA, C., Philipson, V., MacKenzie, E. T., & Seylaz, J. (1989) · Brain Research · doi:10.1016/0006-8993(89)90083-8 · Cited by 93
Iulita, M. F., Millón, M. B. B., Pentz, R., Aguilar, L. F., Carmo, S. D., Allard, S. T. M., Michalski, B., Wilson, E. N., Ducatenzeiler, A., Bruno, M. A., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.08.019 · Cited by 90
Self-citationMoore, A. E., Patterson, C., Lee, L. S., Vedel, I., & Bergman, H. (2014) · Europe PMC (PubMed Central) · Cited by 89
Claassen, J. A. H. R., & Jansen, R. W. M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.3.267 · Cited by 86
Mesulam, M. M. (1976) · Journal of Histochemistry & Cytochemistry · doi:10.1177/24.12.826585 · Cited by 85
Self-citationCholinesterase inhibitors for mild cognitive impairment
Russ, T. C., & Morling, J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009132 · Cited by 85
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · cited 1×
“These observations are supported by other long-term data showing declines in cognitive and global functioning were slower with the persistent use of donepezil over a mean follow-up period of 3 years (Wallin et al., 2007).”
ResultLim, Y. Y., Maruff, P. T., Schindler, R. J., Ott, B. R., Salloway, S., Yoo, D. C., Noto, R. B., Santos, C. Y., & Snyder, P. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.07.009 · Cited by 84
Self-citationRealistic expectations for treatment success in Alzheimer's disease.
Geldmacher, D., Frölich, L., Doody, R. S., Erkinjuntti, T., Vellas, B. J., Jones, R. W., Banerjee, S., Lin, P., & Sano, M. C. (2006) · PubMed · Cited by 82
Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies
Graff-Radford, J., Boeve, B. F., Pedraza, O., Ferman, T. J., Przybelski, S., Lesnick, T. G., Vemuri, P., Senjem, M. L., Smith, G. E., Knopman, D. S., et al. (2012) · Brain · doi:10.1093/brain/aws173 · Cited by 79
NGF-Cholinergic Dependency in Brain Aging, MCI and Alzheimers Disease
Cuello, A., Bruno, A., & Bell, K. F. (2007) · Current Alzheimer Research · doi:10.2174/156720507781788774 · Cited by 79
Self-citationFarlow, M. R., Grossberg, G. T., Sadowsky, C. H., Meng, X., & Somogyi, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12158 · Cited by 78
Self-citationEffect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
Richter, N., Beckers, N., Onur, O. A., Dietlein, M., Tittgemeyer, M., Kracht, L., Neumaier, B., Fink, G. R., & Kukolja, J. (2018) · Brain · doi:10.1093/brain/awx356 · Cited by 77 · cited 2×
“The demonstration of early involvement (Schmitz et al., 2016; Richter et al., 2018) of the cholinergic system starting at preclinical stages of the disease, suggests that cholinomimetics, along with anti-amyloid and anti-tau interventions, may each have a distinct role in disease prevention.”
BackgroundŁojkowska, W., Ryglewicz, D., Jedrzejczak, T., Kotapka-Minc, S., Jakubowska, T., Sienkiewicz‐Jarosz, H., & Bochyńska, A. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(03)00229-6 · Cited by 76
GSK-3α/β kinases and amyloid production in vivo
Jaworski, T., Dewachter, I., Lechat, B., Gees, M., Kremer, A., Demedts, D., Borghgraef, P., Devijver, H., Kügler, S., Patel, S., et al. (2011) · Nature · doi:10.1038/nature10615 · Cited by 75
Mitsushima, D., Mizuno, T. M., & Kimura, F. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00572-2 · Cited by 74
Ikonomovic, M. D., Abrahamson, E. E., Isanski, B. A., Wuu, J., Mufson, E. J., & DeKosky, S. T. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1312 · Cited by 71
Whitehair, D. C., Sherzai, A., Emond, J., Raman, R., Aisen, P. S., Petersen, R. C., Fleisher, A. S., & Study, A. D. C. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.12.003 · Cited by 70
Mucha, L., Wang, S. S., Cuffel, B., McRae, T., Mark, T. L., & Valle, M. D. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.5.451 · Cited by 69
Feldman, H. H., Pirttila, T., Dartigues, J. F., Everitt, B., Van Baelen, B., Schwalen, S., & Kavanagh, S. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2141 · Cited by 67
Ebmeier, K. P., Hunter, R., Curran, S., Dougall, N., Murray, C. L., Wyper, D., Patterson, J. C., Hanson, M. T., Siegfried, K., & Goodwin, G. M. (1992) · Psychopharmacology · doi:10.1007/bf02245293 · Cited by 66
Long-term progression of Alzheimer's disease in patients under antidementia drugs
Gillette‐Guyonnet, S., Andrieu, S., Nourhashemi, F., Gardette, V., Coley, N., Cantet, C., Gauthier, S., Ousset, P., Vellas, B., & REAL.FR study group (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.02.009 · Cited by 64
Cumbo, E., & Ligori, L. D. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131190 · Cited by 63
Slow-wave sleep, acetylcholine, and memory consolidation
Power, A. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400237101 · Cited by 63
Espada, S., Rojo, A. I., Salinas, M., & Cuadrado, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06208.x · Cited by 62
Sabbagh, M., & Cummings, J. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-21 · Cited by 61
Renin Angiotensin System in Cognitive Function and Dementia
Bodiga, V. L., & Bodiga, S. (2013) · Asian Journal of Neuroscience · doi:10.1155/2013/102602 · Cited by 57
Cholinergic Surveillance over Hippocampal RNA Metabolism and Alzheimer's-Like Pathology
Kolisnyk, B., Al-Onaizi, M., Soreq, L., Barbash, S., Bekenstein, U., Haberman, N., Hanin, G., Kish, M. T., Souza da Silva, J., Fahnestock, M., et al. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw177 · Cited by 57
Salehi, A., Dubelaar, E. J. G., Mulder, M., & Swaab, D. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11445 · Cited by 52
Cavedo, E., for the Hippocampus Study Group, Dubois, B., Colliot, O., Lista, S., Croisile, B., Tisserand, G. L., Touchon, J., Bonafe, A., Ousset, P. J., et al. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10413 · Cited by 51
Self-citationVaucher, E., Borredon, J., Bonvento, G., Seylaz, J., & Lacombe, P. M. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199706000-00010 · Cited by 47
Adler, G., Mueller, B., & Articus, K. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12374 · Cited by 47
A population-based study of dosing and persistence with anti-dementia medications
Brewer, L., Bennett, K., McGreevy, C., & Williams, D. J. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1483-y · Cited by 46
van den Bussche, H., Kaduszkiewicz, H., Koller, D., Eisele, M., Steinmann, S., Glaeske, G., & Wiese, B. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328344c600 · Cited by 45
Dubelaar, E. J. G., Verwer, R. W. H., Hofman, M. A., Van Heerikhuize, J. J., Ravid, R., & Swaab, D. F. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.2.159 · Cited by 45
Cissé, M., Braun, U., Leitges, M., Fisher, A., Pagès, G., Checler, F., & Vincent, B. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.04.008 · Cited by 44
Alzheimer's Disease Management Guideline: Update 2008
Segal‐Gidan, F., Cherry, D., Jones, R., Williams, B., Hewett, L., & Chodosh, J. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.07.005 · Cited by 43
Prevalence of cholinesterase inhibitors in subjects with dementia in Europe
Pariente, A., Helmer, C., Merliere, Y., Moore, N., Fourrier‐Réglat, A., & Dartigues, J. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1613 · Cited by 42
Triaca, V., & Calissano, P. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.193224 · Cited by 40
Reply: the early pathological process in sporadic Alzheimer’s disease
Braak, H., & Tredici, K. D. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1170-1 · Cited by 37
APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer’s Disease
Waring, J. F., Tang, Q., Robieson, W., King, D. P., Das, U., Dubow, J. S., Dutta, S., Marek, G. J., & Gault, L. M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142589 · Cited by 37
Effect of Donepezil on Cognition in Severe Alzheimer's Disease: A Pooled Data Analysis
Cummings, J., Jones, R., Wilkinson, D., Lopez, O., Gauthier, S., Waldemar, G., Zhang, R., Xu, Y., Sun, Y., Richardson, S., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100078 · Cited by 36
Uusvaara, J., Pitkälä, K. H., Tienari, P. J., Kautiainen, H., Tilvis, R. S., & Strandberg, T. E. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.02129.x · Cited by 36
Bott, J.-B., Héraud, C., Cosquer, B., Herbeaux, K., Aubert, J., Sartori, M., Goutagny, R., & Mathis, C. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1174-16.2016 · Cited by 36
Härtig, W., Saul, A., Kacza, J., Grosche, J., Goldhammer, S., Michalski, D., & Wirths, O. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12050 · Cited by 34
Miranda, L. F. J. R., Gomes, K. B., Silveira, J. N., Pianetti, G. A., Byrro, R. M. D., Peles, P. R. H., Pereira, F. H., Santos, T. R., Assini, A. G., Ribeiro, V. V., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142148 · Cited by 34
Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010
Zilkens, R., Duke, J. M., Horner, B., Semmens, J. B., & Bruce, D. G. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.001 · Cited by 34
Schoenmakers, B., Buntinx, F., & Lepeleire, J. D. (2009) · Family Practice · doi:10.1093/fampra/cmp024 · Cited by 33
Nonmedical Influences on the Use of Cholinesterase Inhibitors in Dementia Care
Franz, C. E., Barker, J. C., Kravitz, R. L., Flores, Y., Krishnan, S., & Hinton, L. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181461955 · Cited by 32
Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia
Ceravolo, R., Volterrani, D., Frosini, D., Bernardini, S., Rossi, C. A., Logi, C., Manca, G., Kiferle, L., Mariani, G., Murri, L., et al. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0478-6 · Cited by 32
Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease
Deardorff, W. J., & Grossberg, G. T. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1215431 · Cited by 32
Self-citationTifratène, K., Duff, F. L., Pradier, C., Quetel, J., Lafay, P., Schück, S., Benzenine, É., Quantin, C., & Robert, P. H. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3303 · Cited by 30
Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors
Robinson, M., Rowett, D. S., Leverton, A., & Mabbott, V. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1739 · Cited by 30
Lacombe, P. M., Sercombe, R., Vaucher, E., & Seylaz, J. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48494.x · Cited by 29
Florencia Iulita, M., Caraci, F., & Claudio Cuello, A. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160321104916 · Cited by 29
Self-citationIs anti-cholinesterase therapy of Alzheimer’s disease delaying progression?
Giacobini, E. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351483 · Cited by 28
Self-citationHashimoto, M., Yatabe, Y., Kaneda, K., Honda, K., & Ikeda, M. (2009) · Psychogeriatrics · doi:10.1111/j.1479-8301.2009.00302.x · Cited by 26
Responses to Donepezil in Alzheimer's Disease and Parkinson's Disease
Mori, S. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04856.x · Cited by 26
Turnbull, M. T., Boskovic, Z., & Coulson, E. J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00051 · Cited by 24
Barbeliview, A., MacKenzie, E. T., & Dauphin, F. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11506-r · Cited by 21
Welt, T., Kulic, L., Hoey, S. E., McAfoose, J., Späni, C., Chadha, A. S., Fisher, A., & Nitsch, R. M. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150152 · Cited by 20
Prescribing trends in cognition enhancing drugs in Australia
Hollingworth, S., & Byrne, G. J. (2010) · International Psychogeriatrics · doi:10.1017/s1041610210001146 · Cited by 19
National patterns of dementia treatment among elderly ambulatory patients.
Maneno, M. K., Lee, E., Wutoh, A. K., Zuckerman, I. H., Jackson, P., Lombardo, F. A., Scott, K. R., & Xue, Z. (2006) · PubMed · Cited by 14
Donepezil and nursing home placement — benefits and costs
Jelić, V., & Winblad, B. G. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.237 · Cited by 14
Giacobini, E. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9551-6_17 · Cited by 14
Self-citationAlzheimer's disease: a treatment in sight?
Lovestone, S., & Howard, R. J. (1995) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.59.6.566 · Cited by 13
Shirayama, Y., Takahashi, M., Oda, Y., Yoshino, K., Sato, K., Okubo, T., & Iyo, M. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9803-y · Cited by 13
Sato, A., & Sato, Y. (1990) · Journal of the Autonomic Nervous System · doi:10.1016/0165-1838(90)90118-3 · Cited by 12
Arahata, H., Ohyagi, Y., Matsumoto, S., Furuya, H., Murai, H., Kuwabara, Y., Nakagawa, M., Yamada, T., & Kira, J. I. (2001) · PubMed · Cited by 11
Severe Alzheimer’s Disease: Treatment Effects on Function and Care Requirements
Kerwin, D. R., & Claus, T. H. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.06.011 · Cited by 8
Physicians' Efficacy Requirements for Prescribing Medications to Persons with Alzheimer's Disease
Oremus, M., Wolfson, C. M., Bergman, H., & Vandal, A. C. (2007) · Canadian Journal on Aging / La Revue canadienne du vieillissement · doi:10.3138/cja.26.2.139 · Cited by 7
Ray, R., & Prettyman, R. J. (2013) · International Psychogeriatrics · doi:10.1017/s104161021300094x · Cited by 5
Atri, A., Cummings, J. L., Hendrix, S. B., Ellison, N., Andersen, K. A., & Edwards, J. G. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.430 · Cited by 2
Cuello, A. C. (2013) · Springer eBooks · doi:10.1007/978-3-642-27772-6_199-2 · Cited by 2
Self-citationSnyder, P. J., Santos, C. Y., Getter, C., Schindler, R. J., Ott, B. R., Salloway, S., Yoo, D. C., Noto, R. B., Lim, Y. Y., & Maruff, P. T. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.431 · Cited by 1
Self-citation
Research works printed but not linked: 1
- Geula, 1994, Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease, 263
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
“As a result, the cholinergic hypothesis is based on three concepts: reduced presynaptic cholinergic markers in the cerebral cortex, severe neurodegeneration of nucleus basalis of Meynert (NBM) in the basal forebrain, which is the source of cortical cholinergic innervation, and the role of cholinergic antagonists in me…”
BackgroundZhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“100,101 Acetylcholine (ACh) is synthesized from choline and acetyl-coenzyme A by ChAT, then transported into synaptic vesicles through the vesicular acetylcholine transporter (VAChT).”
BackgroundSex differences in Alzheimer disease — the gateway to precision medicine
for the Women’s Brain Project and the Alzheimer Precision Medicine Initiative, Ferretti, M. T., Iulita, M. F., Cavedo, E., Chiesa, P. A., Schumacher Dimech, A., Santuccione Chadha, A., Baracchi, F., Girouard, H., Misoch, S., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0032-9 · Cited by 1,009
Self-citationCurrent and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Chen, Y., Xu, J., & Chen, Y. (2021) · Nutrients · doi:10.3390/nu13062099 · Cited by 917
“Its dysregulation is closely associated with neurodegenerative diseases such as AD [55,56].”
Background
Metadata
- Authors
- Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., & Khachaturian, Z. S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Northwestern University (US)
- McGill University (CA)
- Indiana University School of Medicine (US)
- University Hospital of Geneva (CH)
- Saint Louis University (US)
- Prevent Alzheimer’s Disease 2020 (US)
- University of Rhode Island (US)
- Corresponding author
- Hampel, Harald
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-05-29
- Volume
- 141
- Issue
- 7
- Pages
- 1917-1933
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6022632
- OpenAlex
- W2805257646
- Cited by
- 1,918
- References
- 179
- Citations by year
- 2026: 245 · 2025: 298 · 2024: 298 · 2023: 328 · 2022: 300 · 2021: 228 · 2020: 130 · 2019: 65 · 2018: 21
- FWCI
- 14.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Brain (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Purdue University Indianapolis (Indiana University) (submittedVersion)
- Funders
- AXA Research Fund
- ‘Fondation pour la Recherche sur Alzheimer’, Paris, France. Ce travail a bénéficié d'une aide de l’Etat ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- ‘Investissements d’avenir’ (ANR-10-IAIHU-06)
- Canadian Institutes of Health Research
- National Research Council
- Alzheimer Society of Canada
- Rotary Club Livorno ‘Mascagni’/The Rotary Foundation (GG1758249)
- ADC (AG013854)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic system, cholinergic hypothesis, cholinesterase inhibitors, acetylcholine, cholinergic denervation, neurofibrillary degeneration, amyloid plaques, cognitive decline, cholinergic drugs, combination therapy
- MeSH terms
- Alzheimer Disease, Cholinesterase Inhibitors, Cognition, Cognition Disorders, Humans, Amyloid beta-Peptides, Neurofibrillary Tangles, Cholinergic Agents, Cholinergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.